✦ LIBER ✦

A New Generation of Serotype Chimeric Infectivity-Enhanced Conditionally Replicative Adenovirals: The Safety Profile of Ad5/3-Δ24 in Advance of a Phase I Clinical Trial in Ovarian Cancer Patients

✍ Scribed by Kim, Kenneth H.; Ryan, Michael J.; Estep, James E.; Miniard, Brock M.; Rudge, Thomas L.; Peggins, James O.; Broadt, Trevor L.; Wang, Minghui; Preuss, Meredith A.; Siegal, Gene P.

Book ID: 115467351
Publisher: Mary Ann Liebert
Year: 2011
Tongue: English
Weight: 490 KB
Volume: 22
Category: Article
ISSN: 1043-0342
DOI: 10.1089/hum.2010.180

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I clinical trial of Ad5/3-Δ24, a

A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer

✍ Kim, Kenneth H.; Dmitriev, Igor P.; Saddekni, Souheil; Kashentseva, Elena A.; Ha 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 608 KB

Identifying the safety profile of a nove

Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Δ24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer

✍ John G. Page; Baohong Tian; Karen Schweikart; Joseph Tomaszewski; Ray Harris; Tr 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 245 KB